Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/46293
Title: | Chemoresistance is mediated by ovarian cancer leader cells in vitro. | Authors: | Karimnia N.;Wilson A.L.;Green E.;Matthews A.;Jobling T.W. ;Plebanski M.;Bilandzic M.;Stephens A.N. | Institution: | (Jobling) Monash Medical Centre, Department of Gynaecology Oncology, Monash Health, Moorabbin, Australia (Karimnia, Wilson, Green, Matthews, Bilandzic, Stephens) Hudson Institute of Medical Research, 27-31 Wright St, Clayton, VIC 3168, Australia (Green, Matthews) Department of Molecular and Translational Sciences, Monash University, Clayton, Australia (Plebanski) School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia |
Issue Date: | 10-Sep-2021 | Copyright year: | 2021 | Publisher: | BioMed Central Ltd | Place of publication: | United Kingdom | Publication information: | Journal of Experimental and Clinical Cancer Research. 40(1) (no pagination), 2021. Article Number: 276. Date of Publication: December 2021. | Journal: | Journal of Experimental and Clinical Cancer Research | Abstract: | Background: Leader cells are a subset of cancer cells that coordinate the complex cell-cell and cell-matrix interactions required for ovarian cancer migration, invasion, tumour deposition and are negatively associated with progression-free survival and response to therapy. Emerging evidence suggests leader cells may be enriched in response to chemotherapy, underlying disease recurrence following treatment. Method(s): CRISPR was used to insert a bicistronic T2A-GFP cassette under the native KRT14 (leader cell) promoter. 2D and 3D drug screens were completed in the presence of chemotherapies used in ovarian cancer management. Leader cell; proliferative (Ki67); and apoptotic status (Cleaved Caspase 3) were defined by live cell imaging and flow cytometry. Quantitative real-time PCR defined "stemness" profiles. Proliferation was assessed on the xCELLigence real time cell analyser. Statistical Analysis was performed using unpaired non-parametric t-tests or one-way ANOVA and Tukey's multiple comparison post hoc. Result(s): Leader cells represent a transcriptionally plastic subpopulation of ovarian cancer cells that arise independently of cell division or DNA replication, and exhibit a "stemness" profile that does not correlate with epithelial-to-mesenchymal transition. Chemotherapeutics increased apoptosis-resistant leader cells in vitro, who retained motility and expressed known chemo-resistance markers including ALDH1, Twist and CD44v6. Functional impairment of leader cells restored chemosensitivity, with leader cell-deficient lines failing to recover following chemotherapeutic intervention. Conclusion(s): Our data demonstrate that ovarian cancer leader cells are resistant to a diverse array of chemotherapeutic agents, and are likely to play a critical role in the recurrence of chemo-resistant disease as drivers of poor treatment outcomes.Copyright © 2021, The Author(s). | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1186/s13046-021-02086-3 | PubMed URL: | 34470672 [http://www.ncbi.nlm.nih.gov/pubmed/?term=34470672] | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/46293 | Type: | Article | Subjects: | analysis of variance apoptosis *cancer cell cancer recurrence cancer stem cell cell division cell motility cell proliferation cell selection cell subpopulation cell viability chemosensitivity clustered regularly interspaced short palindromic repeat correlation analysis DNA replication drug screening enzyme degradation epithelial mesenchymal transition flow cytometry IC50 in vitro study live cell imaging nonparametric test *ovary cancer/dr [Drug Resistance] post hoc analysis promoter region protein expression real time polymerase chain reaction treatment outcome aldehyde dehydrogenase isoenzyme 1/ec [Endogenous Compound] *antineoplastic agent carboplatin/pd [Pharmacology] caspase 3/ec [Endogenous Compound] CD133 antigen/ec [Endogenous Compound] CD44v6 antigen/ec [Endogenous Compound] cisplatin/pd [Pharmacology] cyclophosphamide/pd [Pharmacology] cytokeratin 14/ec [Endogenous Compound] DNA/ec [Endogenous Compound] doxorubicin/pd [Pharmacology] epithelial cell adhesion molecule/ec [Endogenous Compound] fibronectin/ec [Endogenous Compound] green fluorescent protein Ki 67 antigen/ec [Endogenous Compound] nerve cell adhesion molecule/ec [Endogenous Compound] Notch receptor/ec [Endogenous Compound] octamer transcription factor 4/ec [Endogenous Compound] olaparib/pd [Pharmacology] paclitaxel/pd [Pharmacology] rucaparib/pd [Pharmacology] stem cell factor receptor/ec [Endogenous Compound] topotecan/pd [Pharmacology] transcription factor NANOG/ec [Endogenous Compound] transcription factor Slug/ec [Endogenous Compound] transcription factor Snail/ec [Endogenous Compound] transcription factor Twist/ec [Endogenous Compound] uvomorulin/ec [Endogenous Compound] vimentin/ec [Endogenous Compound] Wnt1 protein/ec [Endogenous Compound] *leader cell |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.